Truist Securities analyst Robyn Karnauskas reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $1045 price target.
Truist Securities maintains Regeneron Pharmaceuticals (NASDAQ:REGN) $1045 price target Read Post »
TD Cowen analyst Gary Taylor maintains Humana (NYSE:HUM) with a Outperform and lowers the price target from $616 to $613.
TD Cowen lowers Humana (NYSE:HUM) price target from $616 to $613 Read Post »
Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:ZTS) with a Overweight and raises the price target from $210 to $220.
Piper Sandler raises Zoetis (NYSE:ZTS) price target from $210 to $220 Read Post »
Jefferies Lifts Price Target on Amgen (NASDAQ:AMGN) to $310 From $275, Maintains Buy Rating.
Jefferies Lifts Price Target on Amgen (NASDAQ:AMGN) to $310 From $275 Read Post »
Needham analyst Mike Matson reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $61 price target.
Needham maintains Boston Scientific (NYSE:BSX) $61 price target Read Post »
Goldman Sachs analyst Nathan Rich maintains Zoetis (NYSE:ZTS) with a Buy and raises the price target from $204 to $213.
Goldman Sachs raises Zoetis (NYSE:ZTS) price target from $204 to $213 Read Post »
Jefferies analyst Akash Tewari upgrades Eli Lilly (NYSE:LLY) from Hold to Buy and announces $615 price target.
Jefferies announces Eli Lilly (NYSE:LLY) $615 price target Read Post »
Goldman Sachs Raises Eli Lilly (NYSE:LLY) Price Target to $470 From $385, Maintains Neutral Rating。
Goldman Sachs Raises Eli Lilly (NYSE:LLY) Price Target to $470 From $385 Read Post »
RBC Capital analyst Trung Huynh maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $490 to $580.
RBC Capital raises Eli Lilly (NYSE:LLY) price target from $490 to $580 Read Post »
UBS Adjusts Gilead Sciences (NASDAQ:GILD) Price Target to $84 From $88, Maintains Neutral Rating。
UBS Adjusts Gilead Sciences (NASDAQ:GILD) Price Target to $84 From $88 Read Post »
Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $350 to $340.
Truist Securities lowers Biogen (NASDAQ:BIIB) price target from $350 to $340 Read Post »
Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $500 to $615.
Wells Fargo raises Eli Lilly (NYSE:LLY) price target from $500 to $615 Read Post »